GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (XBRU:TUB) » Definitions » EV-to-EBIT

Financiere de Tubize (XBRU:TUB) EV-to-EBIT : 47.30 (As of May. 04, 2024)


View and export this data going back to 1985. Start your Free Trial

What is Financiere de Tubize EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Financiere de Tubize's Enterprise Value is €4,325.13 Mil. Financiere de Tubize's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €91.45 Mil. Therefore, Financiere de Tubize's EV-to-EBIT for today is 47.30.

The historical rank and industry rank for Financiere de Tubize's EV-to-EBIT or its related term are showing as below:

XBRU:TUB' s EV-to-EBIT Range Over the Past 10 Years
Min: 0   Med: 0   Max: 48.18
Current: 47.31

During the past 13 years, the highest EV-to-EBIT of Financiere de Tubize was 48.18. The lowest was 0.00. And the median was 0.00.

XBRU:TUB's EV-to-EBIT is ranked worse than
84.33% of 434 companies
in the Biotechnology industry
Industry Median: 8.915 vs XBRU:TUB: 47.31

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Financiere de Tubize's Enterprise Value for the quarter that ended in Dec. 2023 was €3,270.18 Mil. Financiere de Tubize's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €91.45 Mil. Financiere de Tubize's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.80%.


Financiere de Tubize EV-to-EBIT Historical Data

The historical data trend for Financiere de Tubize's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Financiere de Tubize EV-to-EBIT Chart

Financiere de Tubize Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.22 14.21 47.38 36.81 35.76

Financiere de Tubize Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.38 - 36.81 - 35.76

Competitive Comparison of Financiere de Tubize's EV-to-EBIT

For the Biotechnology subindustry, Financiere de Tubize's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Financiere de Tubize's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Financiere de Tubize's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Financiere de Tubize's EV-to-EBIT falls into.



Financiere de Tubize EV-to-EBIT Calculation

Financiere de Tubize's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4325.127/91.445
=47.30

Financiere de Tubize's current Enterprise Value is €4,325.13 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Financiere de Tubize's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €91.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Financiere de Tubize  (XBRU:TUB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Financiere de Tubize's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=91.445/3270.17842
=2.80 %

Financiere de Tubize's Enterprise Value for the quarter that ended in Dec. 2023 was €3,270.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Financiere de Tubize's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €91.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Financiere de Tubize EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Financiere de Tubize's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Financiere de Tubize (XBRU:TUB) Business Description

Traded in Other Exchanges
Address
Allée de la Recherche, 60, Brussels, BEL, 1070
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize (XBRU:TUB) Headlines

No Headlines